TCRX
Tscan Therapeutics Inc
NASDAQ: TCRX · HEALTHCARE · BIOTECHNOLOGY
$1.15
-8.73% today
Updated 2026-04-29
Market cap
$75.73M
P/E ratio
—
P/S ratio
7.33x
EPS (TTM)
$-1.00
Dividend yield
—
52W range
$1 – $3
Volume
0.9M
Tscan Therapeutics Inc (TCRX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
-40.2%
Last 4 quarters
Revenue YoY growth
+286.0%
Most recent quarter
EPS YoY growth
+40.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-5.8%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-7.4%
2025-11-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-11 | $-0.18 | +32.6% | $1.18 | $1.13 | -4.2% |
| 2025-11-12 | $-0.28 | +17.6% | $1.22 | $1.13 | -7.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.27 | $-0.18 | +32.6% | $2.57M | +286.0% |
| 2025-09-30 | $-0.34 | $-0.28 | +17.6% | $2.51M | +139.4% |
| 2025-06-30 | $-0.33 | $-0.65 | -97.0% | $3.08M | +473.9% |
| 2025-03-31 | $-0.28 | $-0.60 | -114.3% | $2.17M | +283.6% |
| 2024-12-31 | $-0.29 | $-0.30 | -3.4% | $665000.00 | -90.8% |
| 2024-09-30 | $-0.31 | $-0.25 | +19.4% | $1.05M | -73.0% |
| 2024-06-30 | $-0.28 | $-0.28 | +0.0% | $536000.00 | -83.0% |
| 2024-03-31 | $-0.26 | $-0.32 | -23.1% | $566000.00 | -91.7% |
| 2023-12-31 | $-0.29 | $-0.21 | +27.6% | $7.21M | — |
| 2023-09-30 | $-0.45 | $-0.24 | +46.7% | $3.89M | — |
| 2023-06-30 | $-0.78 | $-0.51 | +34.6% | $3.15M | — |
| 2023-03-31 | $-0.74 | $-0.93 | -25.7% | $6.80M | — |
| 2022-12-31 | $-0.70 | $-0.78 | -11.4% | — | — |
Frequently asked questions
Has Tscan Therapeutics Inc beaten earnings estimates?
Tscan Therapeutics Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of -40.2% over the last 4 quarters.
How does TCRX stock react to earnings?
TCRX stock has moved an average of -5.8% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Tscan Therapeutics Inc's revenue growth rate?
Tscan Therapeutics Inc reported year-over-year revenue growth of +286.0% in its most recent quarter, with EPS growing +40.0% year-over-year.